- <![CDATA[Clinical Scenario Presentation and Treatment Approach for Progressive Disease]]><![CDATA[Experts weigh mutation testing, comorbidities, and patient preference to guide second-line CLL options after BTK inhibitor resistance.]]>onclive · 2mo ago↗ source
- <![CDATA[Dr Pant on the Mechanism of Action of Daraxonrasib in PDAC]]><![CDATA[Shubham Pant, MD, MBBS, explains the unique "on-state" binding mechanism of daraxonrasib.]]>onclive · 2mo ago↗ source
- <![CDATA[Four-Year Follow-Up Outcomes in dMMR Endometrial Cancer Presented at SGO 2026]]><![CDATA[SGO 2026 data shows frontline checkpoint inhibitors in dMMR gynecologic cancer drive flat survival curves, hinting at cure and less chemo.]]>onclive · 2mo ago↗ source